Skip to main content

Mega deal: La Jolla startup Synthorx sells for $2.5 billion to Sanofi

By The San Diego Union-Tribune  
   December 10, 2019

In the largest local biotech deal of the year, French pharmaceutical giant Sanofi is acquiring La Jolla’s cancer drug startup Synthorx for $2.5 billion. The 5-year-old startup has been working in the field of synthetic biology, expanding the genetic code to give its researchers more building blocks to create novel drugs. Synthorx just went public in late 2018, raising $131 million in its initial public offering.

Full story

Get the latest on healthcare leadership in your inbox.